Therapeutic cancer vaccines: are we there yet?
- 28 December 2010
- journal article
- review article
- Published by Wiley in Immunological Reviews
- Vol. 239 (1), 27-44
- https://doi.org/10.1111/j.1600-065x.2010.00979.x
Abstract
Summary: Enthusiasm for therapeutic cancer vaccines has been rejuvenated with the recent completion of several large, randomized phase III clinical trials that in some cases have reported an improvement in progression free or overall survival. However, an honest appraisal of their efficacy reveals modest clinical benefit and a frequent requirement for patients with relatively indolent cancers and minimal or no measurable disease. Experience with adoptive cell transfer‐based immunotherapies unequivocally establishes that T cells can mediate durable complete responses, even in the setting of advanced metastatic disease. Further, these findings reveal that the successful vaccines of the future must confront: (i) a corrupted tumor microenvironment containing regulatory T cells and aberrantly matured myeloid cells, (ii) a tumor‐specific T‐cell repertoire that is prone to immunologic exhaustion and senescence, and (iii) highly mutable tumor targets capable of antigen loss and immune evasion. Future progress may come from innovations in the development of selective preparative regimens that eliminate or neutralize suppressive cellular populations, more effective immunologic adjuvants, and further refinement of agents capable of antagonizing immune check‐point blockade pathways.Keywords
This publication has 150 references indexed in Scilit:
- Differentiation and Persistence of Memory CD8+ T Cells Depend on T Cell Factor 1Immunity, 2010
- “MIATA”—Minimal Information about T Cell AssaysImmunity, 2009
- Adoptive cell therapy for the treatment of patients with metastatic melanomaCurrent Opinion in Immunology, 2009
- The diversity of costimulatory and inhibitory receptor pathways and the regulation of antiviral T cell responsesCurrent Opinion in Immunology, 2009
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastomaNature Medicine, 2008
- High‐dose interleukin‐2 for the treatment of metastatic renal cell carcinomaCancer, 2008
- Lineage relationship and protective immunity of memory CD8 T cell subsetsNature Immunology, 2003
- Mutations of the BRAF gene in human cancerNature, 2002
- Two subsets of memory T lymphocytes with distinct homing potentials and effector functionsNature, 1999